You are here:Home
»
Antibodies
»
Abs to Cancer Markers
»
Anti -CA15-3 Cancer Antigen (Breast Cancer)
Anti -CA15-3 Cancer Antigen (Breast Cancer)
Pricing
For pricing information, USA customers sign in. Outside USA? Please contact your distributor for pricing. Specifications
| Clone |
Host |
Grade |
Applications |
| Monoclonal |
Mouse |
Purified |
IH |
|
| The DF3 antigen is present in high levels on apical borders of differentiated secretory mammary epithelial cells and in the cytosol of less differentiated cells. Malignant tumors display cytoplasmic expression while in benign tumors, expression is seen on apical surfaces. | | | Catalog # | C0050-32B | | Application | Suitable for use in Immunohistochemistry. Other applications have not been tested. | | Recommended Dilutions | Immunohistochemistry (Formalin/paraffin): 1:40 for biotin based detection systems. Pre-treatment is not required. For optimal staining, primary antibody should be incubated 20-60 minutes at RT. | | Optimal dilutions to be determined by researcher. | | Positive Control | Infiltrating ductal human breast carcinoma. | | Storage and Stability | May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap | | CAS Number | n/a | | Clone Type | Monoclonal | | Isotype | IgG1 | | Clone No | 6D184 | | Host | Mouse | | Source | Human | | Concentration | Not Determined | | Form | Supplied as a liquid in PBS, pH 7.2, BSA, 0.1% sodium azide | | Purity | Purified | | Immunogen | Membrane-enriched fraction of a human carcinoma metastatic to the liver. | | Specificity | Recognizes human DF3 antigenic determinant (290kD), a portion of a 20aa tandemly repeated sequence present on the core protein of an epithelial cell-associated mucin (MAM-6). Reacts with a large proportion of primary breast carcinomas and breast tumors metastatic to axillary lymph nodes or distant sites, and with 95% of benign, borderline and malignant tumors of the ovary. Reactivity with lung and colorectal carcinomas has also been demonstrated. | | | Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
External Links
|
